These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study. Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238 [TBL] [Abstract][Full Text] [Related]
4. Information on Genetic Variants Does Not Increase Identification of Individuals at Risk of Esophageal Adenocarcinoma Compared to Clinical Risk Factors. Kunzmann AT; Cañadas Garre M; Thrift AP; McMenamin ÚC; Johnston BT; Cardwell CR; Anderson LA; Spence AD; Lagergren J; Xie SH; Smyth LJ; McKnight AJ; Coleman HG Gastroenterology; 2019 Jan; 156(1):43-45. PubMed ID: 30243622 [TBL] [Abstract][Full Text] [Related]
5. ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality. Salati M; Venetis K; Fassan M; Malapelle U; Pagni F; Sajjadi E; Fusco N; Ghidini M Future Oncol; 2021 Nov; 17(33):4607-4618. PubMed ID: 34406032 [TBL] [Abstract][Full Text] [Related]
6. New ESMO scale ranks mutations as cancer medicine targets. Fricker J Lancet Oncol; 2018 Oct; 19(10):e513. PubMed ID: 30177495 [No Abstract] [Full Text] [Related]
7. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer. Pishvaian MJ; Brody JR Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752 [TBL] [Abstract][Full Text] [Related]
8. Multigene Panel Testing in Oncology Practice: How Should We Respond? Kurian AW; Ford JM JAMA Oncol; 2015 Jun; 1(3):277-8. PubMed ID: 26181167 [No Abstract] [Full Text] [Related]
9. Using Somatic Mutations to Guide Treatment Decisions: Context Matters. Horlings HM; Shah SP; Huntsman DG JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166 [No Abstract] [Full Text] [Related]
10. Predicting response to neoadjuvant therapy in esophageal cancer with p53 genotyping: a fortune-teller's crystal ball or a viable prognostic tool? Nason KS J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2286-7. PubMed ID: 25444198 [No Abstract] [Full Text] [Related]
11. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer. Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S J BUON; 2013; 18(1):116-23. PubMed ID: 23613396 [TBL] [Abstract][Full Text] [Related]
12. Gefitinib-sensitizing mutations in esophageal carcinoma. Guo M; Liu S; Lu F N Engl J Med; 2006 May; 354(20):2193-4. PubMed ID: 16707764 [No Abstract] [Full Text] [Related]
13. Personalized targeted therapy for esophageal squamous cell carcinoma. Kang X; Chen K; Li Y; Li J; D'Amico TA; Chen X World J Gastroenterol; 2015 Jul; 21(25):7648-58. PubMed ID: 26167067 [TBL] [Abstract][Full Text] [Related]
14. Applications of Genomic Sequencing in Pediatric CNS Tumors. Bavle AA; Lin FY; Parsons DW Oncology (Williston Park); 2016 May; 30(5):411-23. PubMed ID: 27188671 [TBL] [Abstract][Full Text] [Related]
15. HER2 amplification status in gastric and gastro-oesophageal junction cancer in routine clinical practice: which sample should be used? Perrone G; Amato M; Callea M; Rabitti C; Righi D; Crucitti P; Coppola R; Onetti Muda A Histopathology; 2012 Jul; 61(1):134-5. PubMed ID: 22551459 [No Abstract] [Full Text] [Related]
16. Gene Mutation Profiling of Breast Cancers for Clinical Decision Making: Drivers and Passengers in the Cart Before the Horse. Stearns V; Park BH JAMA Oncol; 2015 Aug; 1(5):569-70. PubMed ID: 26182336 [No Abstract] [Full Text] [Related]